Page 14 - Eceptor News Today

A groundbreaking study by researchers at Case Western Reserve University suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC).

Study examines the efficacy of anastrozole in preventing breast cancer in postmenopausal women at high risk, focusing on the role of baseline estradiol levels and their impact on treatment outcomes.

While regular screenings may decrease the chance of diagnosis of advanced breast cancer in some women and lead to a 20% reduction in breast cancer mortality, other women will be diagnosed with advanced breast cancer despite screening at regular intervals.

Mortality related to end stage liver disease is ranked as the 12th most common cause of death in the U.S. Liver transplantation remains the only treatment for end stage liver disease, but there is a critical shortage of organ donors, necessitating a dire need for new forms of treatment.

Aging is associated with chronic, nonresolving inflammation, or "inflammaging," that can lead to tissue dysfunction.

People with chronic pain are often dependent on drugs from the class of opioids with sometimes considerable side effects.

Researchers assessed CSX-1004, a monoclonal antibody (mAb), for its efficacy in reversing fentanyl overdose based on its high affinity for fentanyl, positive animal model results, and safe pharmacokinetic profile, positioning it as a potential solution in the opioid crisis.

Almost all postmenopausal patients aged 50-69 years with stage I hormone receptor (HR)-positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease free five years after surgery, according to results from the IDEA clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

A study in Scientific Reports investigates the association between proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RA) use on chronic kidney disease (CKD) risk.